Viking Therapeutics

205 articles about Viking Therapeutics

• Viking Therapeutics to Participate in Upcoming Investor Conferences - May 27, 2020

  5/27/2020

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in two upcoming investor conferences.

• Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

  5/12/2020

  Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced a change to its 2020 Annual Meeting of Stockholders.  

• Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

  4/30/2020

  Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2020,

• Viking Therapeutics to Participate in Upcoming Investor Conferences on May 2020

  4/28/2020

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in two upcoming investor conferences.

• Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020

  4/23/2020

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will release financial results for the first quarter 2020, after the market close on Thursday, April 30, 2020.

• Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference

  4/7/2020

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in the Needham & Company 19 th Annual Healthcare Conference.  The conference, which will take place Apr

• Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

  2/26/2020

  Viking Therapeutics, Inc. announced its financial results for the fourth quarter and year ended December 31, 2019, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Participate in Upcoming Investor Conferences on March 2020

  2/24/2020

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in four upcoming investor conferences.

• Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020

  2/19/2020

  Conference Call Scheduled for Wednesday, February 26 at 4:30 p.m. Eastern Time

• Viking Therapeutics to Present at Biotech Showcase 2020

  1/6/2020

  Viking Therapeutics, Inc. announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at Biotech Showcase™ 2020, being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.

• Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

  11/19/2019

  Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2b clinical trial of VK2809, its novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH)

• Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

  11/5/2019

  Viking Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2019, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019

  10/31/2019

  Conference Call Scheduled for Tuesday, November 5 at 8:30 a.m. Eastern Time

• Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference

  9/25/2019

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will deliver a corporate presentation at the 2019 Cantor Global Healthcare Conference, being held October 2-4, 2019 in New York, NY. 

• 

  Researchers Target NAFLD, NASH Using Lab-on-a-Chip Technology

  8/30/2019

  For years, companies have struggled to develop treatments for non-alcoholic fatty liver disease (NAFLD), a disease that is growing across the world and is predicted to become the main cause of chronic liver problems and the need for liver transplantation.

• Viking Therapeutics to Participate in Upcoming Investor Conferences - Aug. 28, 2019

  8/28/2019

  Viking Therapeutics, Inc. announced that the company will participate in two upcoming investor conferences.

• Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

  8/1/2019

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter ended June 30, 2019, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019

  7/25/2019

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2019, after the market close on Thursday, August 1, 2019.

• Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors

  7/2/2019

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Kathy Rouan, Ph.D., to its board of directors

• Viking Therapeutics to Participate in Upcoming Investor Conferences - May 28, 2019

  5/28/2019

  Viking Therapeutics, Inc. announced that the company will participate in three upcoming investor conferences.